{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-010016","form_type":"8-K","ticker":"ANIX","cik":"0000715446","company_name":"Anixa Biosciences Inc","filed_at":"2022-04-15T23:59:59+00:00","discovered_at":"2026-05-14T18:04:03.446955+00:00","generated_at":"2026-06-26T07:13:54.038054+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Anixa promotes CFO/COO Michael Catelani to President; salary $434,512","bullets":["Michael Catelani promoted to President effective April 14, 2022; retains roles as COO and CFO.","Annual base salary increased to $434,512; granted option to purchase 100,000 shares at closing price.","Stock option vests over 36 months, ten-year term, cashless exercise permitted.","Dr. Amit Kumar steps down as President but remains Chairman and CEO; no related-party transactions."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-010016","json":"https://secwatch.observer/filing/0001493152-22-010016.json","markdown":"https://secwatch.observer/filing/0001493152-22-010016.md","text":"https://secwatch.observer/filing/0001493152-22-010016.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/715446/000149315222010016/0001493152-22-010016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/715446/000149315222010016/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T07:13:54.038054+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7ae0a8c18d","claim":"Michael Catelani changed role as President at Anixa Biosciences Inc.","evidence_excerpt":"On April 14, 2022, the Board of Directors of Anixa Biosciences, Inc. (“we,” “us,” “our,” or the “Company”) promoted Michael Catelani, the current Chief Operating Officer and Chief Financial Officer of the Company, to President of the Company effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/715446/000149315222010016/0001493152-22-010016-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"promoted"},{"label":"Role","value":"President"}],"fact_type":"executive_change"},{"claim_id":"fed0470c97","claim":"Amit Kumar changed role as President at Anixa Biosciences Inc.","evidence_excerpt":"Mr. Catelani is replacing Dr. Amit Kumar, the prior President and current Chairman and Chief Executive Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/715446/000149315222010016/0001493152-22-010016-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"replaced"},{"label":"Role","value":"President"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}